Related Experiment Videos
Nosocomial diarrhoea due to Clostridium difficile
1Department of Microbiology, The University of Western Australia and Western Australian Centre for Pathology and Medical Research, Nedlands, Western Australia, Australia. triley@cyllene.uwa.edu.au
Current Opinion in Infectious Diseases
|July 9, 2004
Summary
Clostridium difficile-associated diarrhea (CDAD) diagnosis remains challenging, but new molecular tests offer promise. While treatment for recurrent CDAD has seen little progress, a vaccine is nearing development, and infection control strategies are crucial for prevention.
Area of Science:
- Infectious Diseases
- Microbiology
- Epidemiology
Background:
- Clostridium difficile is a significant cause of nosocomial infections worldwide.
- Nosocomial diarrhea due to Clostridium difficile remains a persistent healthcare challenge.
Purpose of the Study:
- To review recent advancements in the diagnosis, epidemiology, treatment, and prevention of Clostridium difficile-associated diarrhea (CDAD).
Main Methods:
- Literature review of recent developments in Clostridium difficile research.
- Analysis of diagnostic challenges and emerging molecular techniques.
- Evaluation of treatment strategies, vaccine development, and infection control measures.
Main Results:
- Diagnostic methods for CDAD are still problematic, with newer molecular techniques showing potential.
- The emergence of Clostridium difficile strains lacking toxin A necessitates improved molecular epidemiology.
- Limited progress in treating recurrent CDAD, but a vaccine is anticipated; enhanced infection control and antibiotic stewardship are key.
- New antibiotic introductions raise concerns regarding CDAD risk.
Conclusions:
- Clostridium difficile continues to be a major nosocomial pathogen globally.
- Effective strategies for reducing exposure to the organism and judicious antibiotic use are vital for controlling CDAD rates.